Instil Bio (TIL) Common Equity (2020 - 2026)
Instil Bio (TIL) posted quarterly Common Equity of $110.7 million for Q1 2026, down 23.61% year-over-year from $144.9 million in Q1 2025, and down 2.78% quarter-over-quarter from $113.9 million in Q4 2025.
Instil Bio (TIL) Common Equity (2020 - 2026) Analysis & Trends
Instil Bio's Common Equity history runs 7 years deep, the most recent figure standing at $110.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 23.61% year-over-year to $110.7 million; the TTM figure through Mar 2026 stood at $110.7 million (down 23.61% YoY), while the FY2025 annual figure was $113.9 million, down 32.8% from the prior year.
- Common Equity for Q1 2026 stood at $110.7 million, down from $113.9 million in the prior quarter.
- The five-year high for Common Equity was $508.6 million in Q1 2022, with the low at $110.7 million in Q1 2026.
- The 5-year median for Common Equity is $205.8 million (2024), against an average of $245.7 million.
- The sharpest annual moves came in 2022 and 2023: Common Equity decreased 23.54% in 2022, then sank 43.0% in 2023.
- Instil Bio's Common Equity stood at $363.6 million in 2022, then sank by 37.89% to $225.8 million in 2023, then fell by 24.97% to $169.4 million in 2024, then sank by 32.8% to $113.9 million in 2025, then slipped by 2.78% to $110.7 million in 2026.
- Business Quant data shows TIL's Common Equity at $110.7 million in Q1 2026, $113.9 million in Q4 2025, and $120.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | Instil Bio | 53.44 Mn | 53.44 Mn | - | 107.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107.38 Mn |
| Mar 31, 2026 | 110.70 Mn |
| Dec 31, 2025 | 113.87 Mn |
| Sep 30, 2025 | 120.42 Mn |
| Jun 30, 2025 | 131.67 Mn |
| Mar 31, 2025 | 144.91 Mn |
| Dec 31, 2024 | 169.44 Mn |
| Sep 30, 2024 | 176.33 Mn |
| Jun 30, 2024 | 195.02 Mn |
| Mar 31, 2024 | 205.83 Mn |
| Dec 31, 2023 | 225.83 Mn |
| Sep 30, 2023 | 234.02 Mn |
| Jun 30, 2023 | 296.52 Mn |
| Mar 31, 2023 | 311.15 Mn |
| Dec 31, 2022 | 363.61 Mn |
| Sep 30, 2022 | 410.59 Mn |
| Jun 30, 2022 | 458.33 Mn |
| Mar 31, 2022 | 508.56 Mn |
| Dec 31, 2021 | 555.20 Mn |
| Sep 30, 2021 | 601.42 Mn |